Table 1

Long-term follow-up of the first Dutch Lupus Nephritis Study

AZA/MPCY
Patients (n)3750
Years of follow-up (median, range)9.6 (0.9–13.2)9.6 (0.1–13.0)
Lost to follow-up (n, %)3 (8%)3 (6%)
Non-sustained doubling of serum creatinine (n, %)8 (22%)5 (10%)
Sustained doubling of serum creatinine (n, %)6 (16%)4 (8%)
Primary treatment failure (n, %)1 (3%)0 (0%)
Renal relapse (n, %)14 (38%)*5 (10%)
 Doubling of serum creatinine43
 Proteinuric flare9*2
 Both1-
Renal relapse rate5.51.2
Second renal relapse (n, %)6 of 12§ (50%)1 of 4§ (25%)
ESRD (n, %)2 (5%)2 (4%)
Death (n, %)6 (16%)5 (10%)
  • * Statistically significant difference (p<0.05) compared to CY group.

  • Lost to follow-up – AZA/MP: week 92, 290, and 328; CY: week 49, 195, and 266.

  • Number of patients with a renal relapse/100 patient-years.

  • § AZA/MP: 1 patient reached ESRD and 1 patient died shortly after first renal relapse; CY: 1 patient reached ESRD shortly after first renal relapse.

  • AZA/MP, azathioprine/methylprednisolone; CY, cyclophosphamide; ESRD, end-stage renal disease.